YTD stock performance of biopharma companies working on COVID March 2020

Of the U.S. biopharmaceutical companies currently developing treatments or vaccines targeting the COVID-19 infection caused by coronavirus, Vir Biotechnology Inc.'s shares have increased by 279 percent as they are in the midst of preclinical testing monoclonal antibodies as a treatment for this disease. This statistic shows the year-to-date stock performance of select biopharmaceutical companies working on COVID-19 treatments or vaccines in the U.S. as of March 11, 2020.